Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

First Draft Of WHO’s Pandemic Treaty: IP Waivers, Tech Transfer & Price Transparency

Executive Summary

A World Health Organization negotiating body will shortly examine the “zero draft” of a proposed pandemic treaty aimed at better preparing the world for future health crises. But the international pharmaceutical industry claims the draft as currently worded could actually undermine equitable access to pandemic countermeasures.

You may also be interested in...



WHO’s Draft Pandemic Treaty Calls For More Regulatory Harmonization

Regulatory convergence and the sharing of dossiers, together with the timely and equitable sharing of pathogens, could help to speed up access to diagnostics, vaccines and medications in pandemic situations, according to the first draft of the World Health Organization’s proposed pandemic treaty.

WHO’s Draft Pandemic Treaty Calls For More Regulatory Harmonization

Regulatory convergence and the sharing of dossiers, together with the timely and equitable sharing of pathogens, could help to speed up access to medicines, vaccines and diagnostics in pandemic situations, according to the first draft of the World Health Organization’s proposed pandemic treaty.

Global Pandemic Treaty: Working Draft To Be Discussed In July

The World Health Organization’s plan to have a global pandemic treaty in place by 2024 is drawing a lot of attention as work continues to produce a working draft by the middle of the year.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS147345

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel